Actuality of juvenile dermatomyositis

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 235-240

  Zouagui, Amine ^a   Abourazzak, Sana ^a   Idrissi, Mounia Lakhdar ^a   Souilmi, Fatima Zohra ^a   Chaouki, Sana ^a   Atmani, Samir ^a   Bouharrou, Abdelhak ^a   Hida , Moustapha ^a  

^a HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Calcinosis; Criteria; Evolution; Juvenile dermatomyositis; Treatment

Indexed keywords

AZATHIOPRINE; CALCIUM; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VITAMIN D;

ADOLESCENT DISEASE; CALCINOSIS; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DERMATOMYOSITIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; ELECTROMYOGRAPHY; HUMAN; KINESIOTHERAPY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; SHORT SURVEY; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ARTHROGRAPHY; CHILD; DERMATOMYOSITIS; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; PROGNOSIS; QUALITY OF LIFE; SEX FACTORS; SKIN;

EID: 79955549822     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.12.007     Document Type: Short Survey

References (47)

1. Mendez E.P., Lipton R., Ramsey-Goldman R., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300-305.
2. McCann L.J., Juggins A.D., Maillard S.M., et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255-1260.
3. Pachman L.M., Abbott K., Sinacore J.M., et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247-253.
4. Peloro T.M., Miller O.F., Hahn T.F., et al. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol 2001, 45:28-34.
5. Sallum A.M., Pivato F.C., Doria-Filho U., et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (RioJ) 2008, 84:68-74.
6. Tabarki B., Ponsot G., Prieur A.M., et al. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol 1998, 2:205-211.
7. Morinishi Y., Oh-Ishi T., Kabuki T., et al. Dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007, 17:413-417.
8. Singh S., Bansal A. Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int 2006, 26:510-515.
9. Hiketa T., Matsumoto Y., Ohashi M., et al. Juvenile dermatomyositis: a statistical study of 114 patients with dermatomyositis. J Dermatol 1992, 19:470-476.
10. Benveniste O., Dubourg O., Herson S. New classifications and pathophysiology of the inflammatory myopathies. Rev Med Interne 2007, 28:603-612. [Article in French].
11. Wedderburn L.R., McHugh N.J., Chinoy H., et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007, 46:1786-1791.
12. Feldman B.M., Rider L.G., Reed A.M., et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212.
13. Stübgen J.P. Interferon alpha and neuromuscular disorders. J Neuroimmunol. 2009, 207:3-17.
14. Pachman L.M., Liotta-Davis M.R., Hong D.K., et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifi cations. Arthritis Rheum 2000, 43:2368-2377.
15. Mamyrova G., O'Hanlon T.P., Sillers L., et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 2008, 58:3941-3950.
16. Lutz J., Huwiler K.G., Fedczyna T., et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol. 2002, 103:260-263.
17. López de Padilla C.M., Vallejo A.N., McNallan K.T., et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007, 56:1658-1668.
18. Wargula J.C. Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. Curr Opin Rheumatol. 2003, 15:595-601.
19. Sallum A.M., Kiss M.H., Silva C.A., et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev. 2006, 5:93-100.
20. Ramanan A.V., Feldman B.M. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002, 14:658-662.
21. Rider L.G., Atkinson J.C. Images in clinical medicine. Gingival and periungual vasculopathy of juvenile dermatomyositis. N Engl J Med 2009, 360:e21.
22. Gerami P., Walling H.W., Lewis J., et al. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007, 157:637-644.
23. Apaz M.T., Saad-Magalhães C., Pistorio A., et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009, 61:509-517.
24. Ruperto N., Ravelli A., Pistorio A., et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4-13.
25. Brown V.E., Pilkington C.A., Feldman B.M., et al. Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 2006, 45:990-993.
26. Gardner-Medwin J.M., Irwin G., Johnson K. MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci. 2009, 1154:52-83.
27. Chérin P., Marie I. New diagnostic criteria and measuring outcome in polymyositis and dermatomyositis. Rev Med Interne 2005, 26:361-367. [Article in French].
28. Troyanov Y., Targoff I.N., Tremblay J.L., et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
29. Gunawardena H., Wedderburn L.R., North J., et al. Clinical associations of autoantibodies to a p155/140kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008, 47:324-328.
30. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292:344-347.
31. Seshadri R., Feldman B.M., Ilowite N., et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008, 59:989-995.
32. Stringer E., Singh-Grewal D., Feldman B.M. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008, 58:3585-3592.
33. Reed A.M., Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs. 2002, 4:315-321.
34. Stringer E., Feldman B.M. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006, 18:503-506.
35. Al-Mayouf S.M., Laxer R.M., Schneider R., et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000, 27:2498-2503.
36. Manlhiot C., Tyrrell P.N., Liang L., et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008, 121:e626-e630.
37. Hassan J., van der Net J.J., van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008, 27:1469-1471.
38. Modesto C., Boronat M., Marsal S., et al. FK-506 in the treatment of unresponsive juvenile dermatomyositis (abs.). Ann Rheum Dis 2000, 59:727-728.
39. Martín Nalda A., Modesto Caballero C., Arnal Guimeral C., et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc) 2006, 127:697-701.
40. Riley P., McCann L.J., Maillard S.M., et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008, 47:877-880.
41. Cooper M.A., Willingham D.L., Brown D.E., et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007, 56:3107-3111.
42. Sulpice M., Deslandre C.J., Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009, 76:24-27.
43. Ambler G.R., Chaitow J., Rogers M., et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005, 32:1837-1839.
44. Slimani S., Abdessemed A., Haddouche A., et al. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2010, 77:70-72.
45. Bughin V., Megharfi W., Prieur A.M. Les outils validés pour le suivi des dermatomyosites juvéniles. MT Pediatr 2006, 1:28-39.
46. Hochberg M.C., Lopez-Acuna D., Gittelsohn A.M. Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum. 1983, 26:1465-1471.
47. Barisić N., Jakić-Razumović J., Harjacek M., et al. Childhood dermatomyositis associated with intracranial tumor and liver cysts. Eur J Paediatr Neurol 2007, 11:76-80.